Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

2013 ◽  
Author(s):  
Richard Riedel
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Metastatic Soft Tissue Sarcoma ◽  
Previously Treated

scholarly journals Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†

2016 ◽  
Vol 47 (2) ◽  
pp. 137-144 ◽  
Author(s):  
Akira Kawai ◽  
Nobuhito Araki ◽  
Yoichi Naito ◽  
Toshifumi Ozaki ◽  
Hideshi Sugiura ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Metastatic Soft Tissue Sarcoma ◽  
Previously Treated

scholarly journals Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020 ◽  
Vol 21 (5) ◽  
pp. 671-684 ◽  
Author(s):  
Ghassan K Abou-Alfa ◽  
Vaibhav Sahai ◽  
Antoine Hollebecque ◽  
Gina Vaccaro ◽  
Davide Melisi ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document